D Kob, J Arndt, A Kriester, M Schwenk, K H Kloetzer
{"title":"[Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation].","authors":"D Kob, J Arndt, A Kriester, M Schwenk, K H Kloetzer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In a randomized prospective clinical study, the authors investigate the results of percutaneous radiotherapy (telecobalt) with two rhythms of fractionation in patients with vesical carcinomas. A one-series irradiation with 1.5 Gy daily (except the weekends) up to a total dose of 60 Gy is compared to a two-series irradiation (in the first series 3 Gy three days per week up to 30 Gy, then irradiation-free interval of four weeks, in the second series 1.5 Gy daily up to a total focal dose of 60 Gy). The five-year survival rates are 52% after one-series irradiation and 39% after two-series irradiation. The surgical treatment consisted in a most radical resection of the vesical tumor by TUTUR, partial resection of the wall, of transvesical tumor resection.</p>","PeriodicalId":21981,"journal":{"name":"Strahlentherapie","volume":"161 11","pages":"673-7"},"PeriodicalIF":0.0000,"publicationDate":"1985-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In a randomized prospective clinical study, the authors investigate the results of percutaneous radiotherapy (telecobalt) with two rhythms of fractionation in patients with vesical carcinomas. A one-series irradiation with 1.5 Gy daily (except the weekends) up to a total dose of 60 Gy is compared to a two-series irradiation (in the first series 3 Gy three days per week up to 30 Gy, then irradiation-free interval of four weeks, in the second series 1.5 Gy daily up to a total focal dose of 60 Gy). The five-year survival rates are 52% after one-series irradiation and 39% after two-series irradiation. The surgical treatment consisted in a most radical resection of the vesical tumor by TUTUR, partial resection of the wall, of transvesical tumor resection.